|
May 7
|
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
|
|
Apr 9
|
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple
|
|
Mar 13
|
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 13
|
Gossamer Bio: Q4 Earnings Snapshot
|
|
Mar 13
|
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
|
|
Mar 12
|
3 Promising Penny Stocks With Over $100M Market Cap
|
|
Mar 3
|
With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners
|
|
Feb 19
|
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
|
|
Jan 1
|
3 US Penny Stocks With Market Caps Over $100M
|
|
Oct 3
|
Several Insiders Invested In Gossamer Bio Flagging Positive News
|
|
Aug 21
|
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
|
|
Aug 21
|
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
|
|
Jul 25
|
Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?
|
|
May 14
|
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
|
|
May 7
|
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Gossamer Bio and Chiesi link for pulmonary hypertension treatment
|
|
May 6
|
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
|
|
May 6
|
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
|
|
May 6
|
Gossamer sells rights to drug it hopes can rival a new Merck therapy
|
|
May 6
|
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
|